<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Bartlett KE</submitter><funding>Medical Research Council</funding><funding>Royal Society</funding><funding>Wellcome Trust</funding><funding>UKRI | Medical Research Council</funding><pagination>e2315597121</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11087757</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>121(19)</volume><pubmed_abstract>Snakebite envenoming is a neglected tropical disease that causes substantial mortality and morbidity globally. The venom of African spitting cobras often causes permanent injury via tissue-destructive dermonecrosis at the bite site, which is ineffectively treated by current antivenoms. To address this therapeutic gap, we identified the etiological venom toxins in &lt;i>Naja nigricollis&lt;/i> venom responsible for causing local dermonecrosis. While cytotoxic three-finger toxins were primarily responsible for causing spitting cobra cytotoxicity in cultured keratinocytes, their potentiation by phospholipases A&lt;sub>2&lt;/sub> toxins was essential to cause dermonecrosis in vivo. This evidence of probable toxin synergism suggests that a single toxin-family inhibiting drug could prevent local envenoming.</pubmed_abstract><journal>Proceedings of the National Academy of Sciences of the United States of America</journal><pubmed_title>Dermonecrosis caused by a spitting cobra snakebite results from toxin potentiation and is prevented by the repurposed drug varespladib.</pubmed_title><pmcid>PMC11087757</pmcid><funding_grant_id>MR/S00016X/1 and MR/L01839X/1</funding_grant_id><funding_grant_id>NIF\R1\192161</funding_grant_id><funding_grant_id>221712/Z/20/Z</funding_grant_id><funding_grant_id>200517/Z/16/Z</funding_grant_id><funding_grant_id>MC_PC_15040</funding_grant_id><funding_grant_id>221708/Z/20/Z</funding_grant_id><funding_grant_id>221712/Z/20/Z and 221708/Z/20/Z</funding_grant_id><pubmed_authors>Jenkins TP</pubmed_authors><pubmed_authors>Albulescu LO</pubmed_authors><pubmed_authors>Casewell NR</pubmed_authors><pubmed_authors>Laprade W</pubmed_authors><pubmed_authors>Hall SR</pubmed_authors><pubmed_authors>Wilkinson MC</pubmed_authors><pubmed_authors>Harrison RA</pubmed_authors><pubmed_authors>Crittenden E</pubmed_authors><pubmed_authors>Dawson CA</pubmed_authors><pubmed_authors>Saviola AJ</pubmed_authors><pubmed_authors>Rasmussen SA</pubmed_authors><pubmed_authors>Gutierrez JM</pubmed_authors><pubmed_authors>Bartlett KE</pubmed_authors><pubmed_authors>Modahl CM</pubmed_authors></additional><is_claimable>false</is_claimable><name>Dermonecrosis caused by a spitting cobra snakebite results from toxin potentiation and is prevented by the repurposed drug varespladib.</name><description>Snakebite envenoming is a neglected tropical disease that causes substantial mortality and morbidity globally. The venom of African spitting cobras often causes permanent injury via tissue-destructive dermonecrosis at the bite site, which is ineffectively treated by current antivenoms. To address this therapeutic gap, we identified the etiological venom toxins in &lt;i>Naja nigricollis&lt;/i> venom responsible for causing local dermonecrosis. While cytotoxic three-finger toxins were primarily responsible for causing spitting cobra cytotoxicity in cultured keratinocytes, their potentiation by phospholipases A&lt;sub>2&lt;/sub> toxins was essential to cause dermonecrosis in vivo. This evidence of probable toxin synergism suggests that a single toxin-family inhibiting drug could prevent local envenoming.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 May</publication><modification>2026-06-01T20:22:21.403Z</modification><creation>2026-05-22T03:08:31.872Z</creation></dates><accession>S-EPMC11087757</accession><cross_references><pubmed>38687786</pubmed><doi>10.1073/pnas.2315597121</doi></cross_references></HashMap>